Plasma samples collected at study baseline were stored at -70 °C and sent to a central laboratory certified by the Centers for Disease Control-National Heart Lung and Blood Institute Lipid Standardization Program.
variation at Lp(a) concentrations of 17.6 mg/dL and 58.1 mg/dL are 3.6% and 1.5%, respectively. The average coefficient of variation (using the overall pooled within-person variance and the overall mean) based on 200 blind duplicate WHI samples was 13.9% for Lp(a) and 5.4% for natural log-transformed (Ln) Lp(a). 2 Hemoglobin A1c (HbA1c) was measured in lysed red blood cells of diabetic women only using turbidimetric immunoinhibition on the Hitachi 917 analyzer (Roche Diagnostics, Indianapolis, IN, U.S.). The reported result is a calculation of the percentage HbA1c in the total hemoglobin. The coefficients of variation at HbA1c values of 5.5% and 9.1% are 1.9% and 3.0%, respectively. The average coefficient of variation (using the overall pooled within-person variance and the overall mean) based on 15 blind duplicate WHI samples was 2.4%. 2 High-sensitivity C-reactive protein (hs-CRP) was measured using an immunoturbidimetric assay on the Hitachi 917 analyzer (Roche Diagnostics, Indianapolis, IN, U.S.), using reagents and calibrators from DiaSorin (Stillwater, MN, U.S.). This assay has a sensitivity of 0.03 mg/L. The coefficients of variation of the assay at concentrations of 0.91 mg/L, 3.07 mg/L, and 13.38 mg/L are 2.8%, 1.6%, and 1.1%, respectively. The average coefficient of variation (using the overall pooled within-person variance and the overall mean) based on 201 blind duplicate WHI samples was 6.2% for hs-CRP and 3.6% for Ln hs-CRP. 2 In order to account for extreme values in hs-CRP that would indicate active underlying inflammatory disease, we repeated the main analysis after excluding 160 women with hs-CRP >20 mg/L.
Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity was measured in a 96-well microplate with a colorimetric substrate that is converted on hydrolysis by the phospholipase enzyme. Lp-PLA2 mass concentration was measured with the automated PLAC test using a latex bead-based immunoturbidimetric assay, which uses 2 monoclonal antibodies specific to Lp-PLA2 in a sandwich assay format. Reagents for both assays were provided by diaDexus (South San Francisco, CA, U.S.) free of charge. Coefficients of variation based on laboratory standards are 4.0% for Lp-PLA2 activity and 5.9% for Lp-PLA2 mass. 6 The average coefficients of the overall pooled within-person variance and the overall mean) based on 201 blind duplicate WHI samples was 12.1% for NT-proBNP and 1.8% for Ln NT-proBNP. 2 In order to account for extreme values in NT-proBNP that would indicate underlying heart failure, we repeated the main analysis after excluding 64 women with age-specific diagnostic levels of NT-proBNP for acute heart failure (>900 pg/mL for age ≤75 years and >1800 pg/mL for age >75 years). 7, 8 Human tissue plasminogen activator (tPA) antigen was measured using an ELISA assay (American Diagnostica, Greenwich, CT, U.S.), an enzymatically amplified 'two-step' sandwich-type immunoassay. This assay has a sensitivity of 2.0 ng/mL. For the present analysis, 410 women (11.7%) with non-detectable levels of tPA antigen were considered to have a level of 1.80 ng/mL. The coefficients of variation of the assay at tPA antigen concentrations of 6.0 ng/mL and 15.0 ng/mL is 5.5% and 4.9%, respectively. The average coefficient of variation (using the overall pooled within-person variance and the overall mean) based on 173 blind duplicate WHI samples was 45.5% for tPA and 15.0% for Ln tPA. Hazard ratios (95% CIs) were adjusted for age and race/ethnicity. CHD, coronary heart disease; CVD, cardiovascular disease; Ln, natural log-transformed; MI, myocardial infarction; SD, standard deviation.
* P<0.05 for equal association with CHD.
9 † P<0.05 for equal association with ischemic stroke.
9 ‡ P<0.05 for equal association with hemorrhagic stroke. These analyses were restricted to CHD and ischemic stroke in white and black women because of the small number of hemorrhagic strokes and other CVD deaths in nonwhites and small number of events in general in other ethnic groups (Table 1 main manuscript) . Hazard ratios (95% CIs) were adjusted for age, treated and untreated systolic blood pressure, total and HDL cholesterol levels, diabetes mellitus, and smoking status. P>0.05 for all comparisons of equal association between CHD and ischemic stroke. 9 CHD, coronary heart disease; CVD, cardiovascular disease; Ln, natural log-transformed; MI, myocardial infarction; SD, standard deviation. Hazard ratios (95% CIs) were adjusted for age and race/ethnicity. Apo, apolipoprotein; CHD, coronary heart disease; CVD, cardiovascular disease; HbA1c, glycated hemoglobin A1c; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; Ln, natural log-transformed; Lp(a), lipoprotein (a); Lp-PLA2, lipoprotein-associated phospholipase A2; NT-proBNP, N-terminal pro-brain natriuretic peptide; SD, standard deviation; tPA, tissue plasminogen activator.
9 ‡ P<0.05 for equal association with hemorrhagic stroke. These analyses were restricted to CHD and ischemic stroke in white and black women because of the small number of hemorrhagic strokes and other CVD deaths in nonwhites and small number of events in general in other ethnic groups (Table 1 main manuscript) . Hazard ratios (95% CIs) were adjusted for age, treated and untreated systolic blood pressure, total and HDL cholesterol levels, diabetes mellitus, and smoking status. Apo, apolipoprotein; CHD, coronary heart disease; CVD, cardiovascular disease; HbA1c, glycated hemoglobin A1c; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; Ln, natural log-transformed; Lp(a), lipoprotein (a); Lp-PLA2, lipoprotein-associated phospholipase A2; NT-proBNP, N-terminal pro-brain natriuretic peptide; SD, standard deviation; tPA, tissue plasminogen activator. * P<0.05 for equal association with CHD.
9 † Apo A-I and Apo B100 substituted non-HDL cholesterol and HDL cholesterol. Figure S1 . Differences in β-estimates between coronary heart disease and stroke hazards for non-laboratory risk factors on the incidence of first cardiovascular manifestations.
Values are differences in age and race/ethnicity adjusted β-estimates 9 between hazards of CHD and ischemic stroke (closed squares) and hemorrhagic stroke (open circles). Estimates are expressed per 1 (log-transformed) standard deviation increase for continuous risk factors. Differences in β-estimates greater than 0 represent greater hazards (or less protective). CHD hazards are considered the reference. See Table S2 for corresponding cause-specific hazard ratios. CHD, coronary heart disease; MI, myocardial infarction. Figure S2 . Differences in β-estimates between coronary heart disease and stroke hazards for laboratorybased risk factors on the incidence of first cardiovascular manifestations.
Values are differences in age and race/ethnicity adjusted β-estimates 9 between hazards of CHD and ischemic stroke (closed squares) and hemorrhagic stroke (open circles). Estimates are expressed per 1 (log-transformed) standard deviation increase. Differences in β-estimates greater than 0 represent greater hazards (or less protective). CHD hazards are considered the reference. See Table S4 for corresponding cause-specific hazard ratios. Apo, apolipoprotein; CHD, coronary heart disease; HbA1c, glycated hemoglobin A1c; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; Lp(a), lipoprotein (a); Lp-PLA2, lipoprotein-associated phospholipase A2; NT-proBNP, N-terminal pro-brain natriuretic peptide; tPA, tissue plasminogen activator;
WBC, white blood cell.
